Investors were impressed by the company's broad-spectrum, IV and oral antifungal drug in a space where few treatment options exist; Phase II trials will start later this year.
Amplyx Pharmaceuticals Inc., which just raised $67m in Series C venture capital, is developing an antifungal drug that hits on a lot of key metrics for biopharmaceutical investors while potentially meeting the need for new agents to treat very sick patients who happen to contract life-threatening infections.
For Amplyx's backers, like Series C lead investor Sofinnova Venture Partners, the San Diego, Calif.-based company's novel drug candidate APX001...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
